<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641873</url>
  </required_header>
  <id_info>
    <org_study_id>D8809001</org_study_id>
    <nct_id>NCT02641873</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI +&#xD;
      Bavacizumab. This study population is adult Japanese patients with metastatic colorectal&#xD;
      cancers in FOLFIRI + Bevacizumab combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by adverse events (AEs), serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by determination of unacceptable toxicity in patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Peak plasma concentration)</measure>
    <time_frame>Day 1: prior to BBI608 and 2,4,6,8,10,12,24 hours after the first dose.</time_frame>
    <description>Cmax (Peak plasma concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24h (Area under the plasma concentration versus time curve)</measure>
    <time_frame>Day 1: prior to BBI608 and 2,4,6,8,10,12,24 hours after the first dose.</time_frame>
    <description>AUC0-24h (Area under the plasma concentration versus time curve)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumour activity</measure>
    <time_frame>6 months(an expected average)</time_frame>
    <description>The radiologic assessments will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST for patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Participants follow-up for progression free survival will occur. Maximum follow-up time is 12 months after the initial administration of the last subject.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <description>240 mg twice daily (480 mg total daily dose)</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofolinate</intervention_name>
    <description>200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).</description>
    <arm_group_label>BBI608 + FOLFIRI +Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A histologically confirmed advanced unresectable, metastatic or recurrent colorectal&#xD;
             carcinoma&#xD;
&#xD;
          2. Evaluable patient by RECISTversion 1.1&#xD;
&#xD;
          3. Stage IV&#xD;
&#xD;
          4. ≥ 20 years of age&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          7. Patients with following organ function within 14 days before enrollment (on the basis&#xD;
             of the most recent data during the period if multiple data are available)&#xD;
&#xD;
               -  Hemoglobin (Hg) ≥ 9.0 g/dL&#xD;
&#xD;
               -  Neutrophil count ≥ 1.5 x 103/μL&#xD;
&#xD;
               -  Platelet count ≥ 10 x 104/μL&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × institutional&#xD;
                  upper limit of normal (ULN) [≤ 5 × ULN in presence of liver metastases ]&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × institutional ULN [≤ 2 × ULN in presence of liver&#xD;
                  metastases ]&#xD;
&#xD;
               -  Creatinine ≤ 1.5 × institutional ULN&#xD;
&#xD;
               -  Proteinuria by dipstick urine analysis ≤ 1+. [ UPCR (Urine Albumin-to-Creatinine&#xD;
                  Ratio) ≤ 1, or protein volume of 24-hour urine collection ≤ 1 g, in the case of&#xD;
                  patients with a 2+ urine dipstick reading]&#xD;
&#xD;
          8. For female patient of child producing potential: Must agree to use contraception or&#xD;
             take measures to avoid pregnancy during the study and for 30 days after the last&#xD;
             protocol treatment dose or 6 months after Bevacizumab treatment.. For male patient of&#xD;
             child producing potential: Must agree to use contraception or take measures to avoid&#xD;
             pregnancy during the study and for 90 days after the last protocol treatment dose or 6&#xD;
             months after Bevacizumab treatment&#xD;
&#xD;
          9. Females of childbearing potential have a negative urine pregnancy test&#xD;
&#xD;
         10. Patients who have provided written voluntary consent in person to participate in this&#xD;
             study after fully receiving and understanding the information about this study,&#xD;
             including study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or hormone therapy, or heart&#xD;
             therapy within 21 days of the first dose of BBI608&#xD;
&#xD;
          2. Major surgery within 28 days prior to first dose&#xD;
&#xD;
          3. Have had a brain metastases with a symptom or requiring treatment&#xD;
&#xD;
          4. Have had coinstantaneously active multiple primary cancer&#xD;
&#xD;
          5. Have had a carcinomatous pleural effusion, ascites, or cardiac effusion requiring&#xD;
             treatment&#xD;
&#xD;
          6. Crohn's disease, ulcerative colitis, small intestine resection, diarrhea (watery&#xD;
             diarrhea), paralysis intestinal, Intestinal obstruction&#xD;
&#xD;
          7. Gastrointestinal perforation, tracheo-oesophageal fistula, fistula&#xD;
&#xD;
          8. Unable or unwilling to swallow BBI608 capsules&#xD;
&#xD;
          9. Uncontrolled inter-current illness (such as Grade 3 active infection, or serious&#xD;
             respiratory disease)&#xD;
&#xD;
         10. Uncontrolled hypertension&#xD;
&#xD;
         11. Patients with recent history of hemoptysis of more than 2.5 mL of red blood within&#xD;
             28days before the enrolment&#xD;
&#xD;
         12. Abnormal ECGs which are clinically significant within 28 days before enrolment&#xD;
&#xD;
         13. Patients who are New York Heart Association (NYHA) functional classes III, or IV, or&#xD;
             unstable angina&#xD;
&#xD;
         14. Patients newly expressing angina within three months (90 days) before the enrolment&#xD;
&#xD;
         15. Have had myocardial infarction within six months (180 days)before the enrolment&#xD;
&#xD;
         16. Administrating with antiarrhythmic drug&#xD;
&#xD;
         17. Patients who are planning to breast-feeding by whichever 30 days after the last&#xD;
             administration of BBI608 or by 6 months after the last administration of Bevacizumab&#xD;
&#xD;
         18. Patients of pregnancy or possibility of pregnancy at current time or possibility of&#xD;
             pregnancy within 6 months after the last administration of Bevacizumab&#xD;
&#xD;
         19. Have received other investigational products or not finished the assessment in any&#xD;
             clinical study within 28 days before enrollment&#xD;
&#xD;
         20. Known severe hypersensitivity to 5-FU/ levofolinate/ irinotecan/Bevacizumab&#xD;
&#xD;
         21. Administration of atazanavir sulfate&#xD;
&#xD;
         22. Prior treatment with BBI608&#xD;
&#xD;
         23. Ineligible for participation in the study in the opinion of the Investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic Colorectal Cancer</keyword>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

